Paper Details

  1. Home
  2. Paper Details

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.

Author: AutorinoRiccardo, De PlacidoSabino, Di LorenzoGiuseppe, FiggWilliam D, FossaSophie D, GiordanoAntonio, GiulianoMario, ImbimboCiro, LabiancaRoberto, LongoNicola, MironeVincenzo, PerdonàSisto

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

While taxanes are the most effective initial treatments for advanced prostate cancer that no longer responds to hormone therapy (hormone-refractory prostate cancer), most patients eventually stop responding to these medications. Despite the lack of approved treatments for this stage, many oncologists continue to treat patients with other therapies after they have stopped responding to docetaxel, a type of taxane.
Paper Details　
Original Abstract of the Article :
Although the taxanes represent the most active agents for the first-line treatment of metastatic hormone-refractory prostate cancer (HRPC), most patients eventually progress while receiving taxane-based treatments. No agents are approved for second-line therapy in HRPC, but common standard practice ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.eururo.2008.01.082

データ提供：米国国立医学図書館（NLM）

Combating Prostate Cancer: A New Approach for Second-Line Treatment

Prostate cancer is a challenging disease to treat, and many patients eventually develop resistance to conventional therapies. This study explores the potential of combining bevacizumab, an anti-angiogenesis drug, with docetaxel, a chemotherapy drug, as a second-line treatment for hormone-refractory prostate cancer. It's like discovering a new oasis in the vast desert of cancer treatment, offering a potential route to combatting this disease.

The study found that this combination therapy showed some promise in treating patients who had progressed after receiving docetaxel alone. However, the researchers emphasize that further research is needed to confirm the efficacy and safety of this combination therapy. This research opens a new avenue for exploring more effective treatment options for patients with advanced prostate cancer.

Hope on the Horizon for Prostate Cancer Treatment

This study offers a glimmer of hope for patients who have developed resistance to conventional prostate cancer treatments. However, it’s important to remember that this is a preliminary study, and more research is needed to confirm the effectiveness of this combination therapy. As always, it’s crucial to discuss your treatment options with your healthcare provider to determine the best course of action for your individual needs.

Dr.Camel's Conclusion

This study investigates the potential of combining bevacizumab with docetaxel for treating hormone-refractory prostate cancer, showing some promise but requiring further research to confirm its effectiveness. It’s a reminder that the journey to find better treatments for cancer continues, and we must remain optimistic about new discoveries on the horizon.

Date :
  1. Date Completed 2009-01-14
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

18276061

DOI: Digital Object Identifier

10.1016/j.eururo.2008.01.082

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.